US 12,071,472 B2
Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
Neil R. Cashman, Vancouver (CA); Steven S. Plotkin, Vancouver (CA); Judith Maxwell Silverman, Whistler (CA); Ebrima Gibbs, Port Moody (CA); and Johanne Kaplan, Sherborn, MA (US)
Assigned to The University of British Columbia, Vancouver (CA); and ProMIS Neurosciences Inc., Toronto (CA)
Appl. No. 16/318,605
Filed by The University of British Columbia, Vancouver (CA); and ProMIS Neurosciences, Inc., Toronto (CA)
PCT Filed Jul. 18, 2017, PCT No. PCT/CA2017/050866
§ 371(c)(1), (2) Date Jan. 17, 2019,
PCT Pub. No. WO2018/014126, PCT Pub. Date Jan. 25, 2018.
Claims priority of provisional application 62/507,633, filed on May 17, 2017.
Claims priority of provisional application 62/507,587, filed on May 17, 2017.
Claims priority of provisional application 62/443,766, filed on Jan. 8, 2017.
Claims priority of provisional application 62/363,566, filed on Jul. 18, 2016.
Claims priority of application No. PCT/CA2016/051303 (WO), filed on Nov. 9, 2016.
Prior Publication US 2020/0172602 A1, Jun. 4, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); A61P 25/00 (2006.01); A61P 25/28 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01); A61K 38/17 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); G01N 33/6854 (2013.01); A61K 38/1716 (2013.01); A61K 39/0007 (2013.01); A61K 2039/505 (2013.01); A61K 49/0008 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 33/6896 (2013.01); G01N 2333/4709 (2013.01); G01N 2800/2821 (2013.01)] 19 Claims
 
1. A method of reducing amyloid beta (A-beta) oligomer propagation, the method comprising contacting a cell or tissue expressing A-beta oligomers with or administering to a subject in need thereof an effective amount of:
an A-beta oligomer specific or selective antibody comprising a light chain variable region and a heavy chain variable region, the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2, and CDR-H3, the light chain variable region comprising complementarity determining regions CDR-L1, CDR-L2, and CDR-L3 and with the amino acid sequences of the CDRs comprising SEQ ID NOs: 74-79 respectively;
to reduce A-beta aggregation, oligomer propagation, or A-beta aggregation and oligomer propagation.